Navigation Links
Booster dose not required for Hepatitis B Vaccination

Alessandro Remo Zanetti and his colleagues from Institute of Virology, Italy has found that Initial vaccination with Hepatitis B produces the required concentrations of circulating antibodies in the blood of the patients for long periods//. The researchers have found that the circulating antibodies against Hepatitis B vaccination are present in the blood for at least 10 years after vaccination. Researchers have concluded that there is no need of booster doses of Hepatitis B in these patients as enough amount of antibodies are present which can give protection in case of Hepatitis B infection. The results of the work have been published in the journal The Lancet.

Viral hepatitis B is a leading cause of acute and chronic liver disease worldwide. The World Health Organization (WHO) estimates that, globally, about 2 billion people have been infected with hepatitis B virus (HBV). More than 350 million people are chronically infected. WHO recommends that all countries should have universal infant or adolescent hepatitis B vaccination integrated into their national immunization programs.

The researchers conducted their trial in 1212 children’s and 446 Italian Air Force Recruits by vaccinating with Hepatitis B vaccination. They found that 64% of children and 89% of the recruits retained protective concentrations of antibodies. The study shows that infant and adolescent immune systems can recall responding to hepatitis B more than 10 years after immunization.

Experts View:

Professor Zanetti concludes: “In light of our findings, the use of routine booster doses of hepatitis B vaccine does not seem necessary to maintain long-term protection in immuno-competent individuals vaccinated as infants and teenagers."

Ding-Shinn Chen, National Taiwan University, Taiwan said, “Unless accumulating data show a significant increase of HBV infection in adolescents or adults who were vaccinated as children, a policy of booster vaccination in a population should not be recommended. We believe that this applies both to hyper-endemic and low endemic areas of the world.”

Source: News wise, The Lancet
'"/>




Related medicine news :

1. Need for Hepatitis Booster Questioned
2. Booster Dose Of Radiotherapy Beneficial In Early Breast Cancer
3. Booster Dose for Chickenpox Vaccine Recommended
4. Care for footwear not required diabetic patients
5. Advanced STD programs required
6. New Stem Cells lines will be required
7. Multi targeted approach required for suicide prevention in adolescents
8. More Funds required for Asian Countries to fight Bird Flu
9. Clergy blasts councilmans required-condom plan
10. Salmeterol - to be used in combination & only when required
11. Vitamin B for Hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... 2016 Bracket , a leading clinical trial ... clinical outcomes platform, Bracket eCOA (SM) 6.0, at the ... – 30, 2016 in Philadelphia , Pennsylvania.  ... Assessment product of its kind to fully integrate with RTSM, ... eCOA 6.0 is a flexible platform for electronic clinical outcomes ...
(Date:6/23/2016)... 23, 2016 Revolutionary technology includes ... Oticon , industry leaders in advanced audiology and hearing ... Oticon Opn ™, the world,s first internet connected hearing ... IoT devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ... number of ,world firsts,: , TwinLink™ - ...
Breaking Medicine Technology: